Global engineering firm Wood has announced the award of a multi-million dollar contract with TEVA Biotech GmbH for a new biotechnological facility in Ulm, Germany.
Wood will supply engineering, procurement, construction management, commissioning and qualification (EPCmQ) to the project.
The plant will produce pharmaceutical ingredients from cell cultures in a new eight-storey building to be constructed within TEVA’s existing biotechnology production site.
The expected completion date will be 2020, while tech transfer is planned to begin in 2021.
Robin Watson, chief executive of Wood, said: “This contract reflects TEVA’s trust in our ability to execute projects of this size in Germany and validates our global expertise in the development of active pharmaceutical ingredient facilities. We will draw upon our local knowledge, global resources, and four decades of experience working with the world’s top drug manufacturers to deliver a state-of-the-art facility to TEVA.”
Recommended for you
